|
US20080261289A1
(en)
*
|
1996-12-13 |
2008-10-23 |
Schering-Plough Corporation |
Compositions comprising viruses and methods for concentrating virus preparations
|
|
US6544769B1
(en)
*
|
1996-12-13 |
2003-04-08 |
Schering Corporation |
Compostions comprising viruses and methods for concentrating virus preparations
|
|
PT1144009E
(pt)
*
|
1998-12-03 |
2003-01-31 |
Avigen Inc |
Excipientes para uso em formulacoes farmaceuticas a base de virus adeno-associado e formulacoes farmaceuticas produzidas com estes excipientes
|
|
US6759050B1
(en)
|
1998-12-03 |
2004-07-06 |
Avigen, Inc. |
Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
|
|
US6225289B1
(en)
*
|
1998-12-10 |
2001-05-01 |
Genvec, Inc. |
Methods and compositions for preserving adenoviral vectors
|
|
BR0009595A
(pt)
*
|
1999-04-09 |
2001-12-26 |
Aventis Pharma Sa |
Composição lìquida ou congelada e utilizaçãoterapêutica ou profilática da mesma
|
|
FR2791999B1
(fr)
*
|
1999-04-09 |
2001-09-07 |
Aventis Pharma Sa |
Composition destinee a la conservation d'adenovirus recombinants infectieux
|
|
US7456009B2
(en)
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
|
CA2399321C
(en)
*
|
2000-03-07 |
2013-04-30 |
Robert K. Evans |
Adenovirus formulations
|
|
US20040101964A1
(en)
*
|
2000-05-10 |
2004-05-27 |
Shigemitsu Takashima |
Method of preparing virus vector
|
|
CA2469623C
(en)
|
2001-12-12 |
2012-05-29 |
F H Faulding & Co Limited |
Composition for the preservation of viruses
|
|
RU2004125283A
(ru)
*
|
2002-01-18 |
2005-06-10 |
Шеринг Акциенгезельшафт (De) |
Стабилизированные композиции аденовируса
|
|
KR100507794B1
(ko)
*
|
2003-02-11 |
2005-08-17 |
한미약품 주식회사 |
고농도 레트로 바이러스 현탁액 제조 방법
|
|
US20070148765A1
(en)
*
|
2003-11-19 |
2007-06-28 |
Evans Robert K |
Preservative-containing virus formulations
|
|
US20070207461A1
(en)
*
|
2004-02-23 |
2007-09-06 |
Crucell Holland B.V. |
Virus Purification Methods
|
|
GB0502661D0
(en)
*
|
2005-02-09 |
2005-03-16 |
Stabilitech Ltd |
A desiccated product
|
|
CN101155915B
(zh)
*
|
2005-04-11 |
2013-12-04 |
克鲁塞尔荷兰公司 |
利用超滤进行病毒纯化
|
|
CN1961961B
(zh)
*
|
2005-11-11 |
2010-05-26 |
深圳市源兴生物医药科技有限公司 |
一种药物制剂及其制备方法
|
|
CN102203242B
(zh)
|
2008-11-03 |
2013-06-12 |
克鲁塞尔荷兰公司 |
产生腺病毒载体的方法
|
|
CN102762721B
(zh)
|
2010-02-15 |
2015-03-11 |
克鲁塞尔荷兰公司 |
用于生产Ad26腺病毒载体的方法
|
|
CA2808556A1
(en)
|
2010-09-20 |
2012-03-29 |
Crucell Holland B.V. |
Therapeutic vaccination against active tuberculosis
|
|
AU2011310838B2
(en)
|
2010-09-27 |
2015-11-05 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
|
DK2646052T3
(en)
*
|
2010-12-02 |
2017-07-17 |
Oncolytics Biotech Inc |
LYOPHILIZED VIRAL FORMULATIONS
|
|
SG190418A1
(en)
|
2010-12-02 |
2013-07-31 |
Oncolytics Biotech Inc |
Liquid viral formulations
|
|
CA2864956C
(en)
|
2012-03-12 |
2021-11-09 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
US9119813B2
(en)
|
2012-03-22 |
2015-09-01 |
Crucell Holland B.V. |
Vaccine against RSV
|
|
JP5845376B2
(ja)
|
2012-03-22 |
2016-01-20 |
クルセル ホランド ベー ヴェー |
Ｒｓｖに対するワクチン
|
|
BR112015000530A2
(pt)
|
2012-07-10 |
2018-08-28 |
Transgene Sa |
vacina de antígeno micobacteriano.
|
|
WO2014009433A1
(en)
|
2012-07-10 |
2014-01-16 |
Transgene Sa |
Mycobacterium resuscitation promoting factor for use as adjuvant
|
|
WO2014174018A1
(en)
|
2013-04-25 |
2014-10-30 |
Crucell Holland B.V. |
Stabilized soluble prefusion rsv f polypeptides
|
|
CA2914792C
(en)
|
2013-06-17 |
2024-02-27 |
Crucell Holland B.V. |
Stabilized soluble pre-fusion rsv f polypeptides
|
|
EP3092000A1
(en)
|
2014-01-09 |
2016-11-16 |
Transgene SA |
Fusion of heterooligomeric mycobacterial antigens
|
|
US9721484B2
(en)
|
2014-06-23 |
2017-08-01 |
Humanetics Innovative Solutions, Inc. |
Shoulder kit assembly for crash test dummy
|
|
DK3169341T3
(da)
|
2014-07-16 |
2019-08-05 |
Transgene Sa |
Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
|
|
US10008130B2
(en)
|
2014-09-17 |
2018-06-26 |
Humanetics Innovative Solutions, Inc. |
Omni-directional shoulder assembly for crash test dummy
|
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
|
PL3283634T3
(pl)
|
2015-04-14 |
2019-10-31 |
Janssen Vaccines & Prevention Bv |
Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem
|
|
CA2991002C
(en)
|
2015-07-07 |
2023-11-28 |
Janssen Vaccines & Prevention B.V. |
Vaccine against rsv
|
|
EA035909B1
(ru)
|
2015-07-07 |
2020-08-31 |
Янссен Вэксинс Энд Превеншн Б.В. |
Стабилизированные растворимые f-полипептиды rsv до слияния
|
|
BR112018070323A2
(pt)
|
2016-04-05 |
2019-01-29 |
Janssen Vaccines & Prevention Bv |
vacina contra rsv
|
|
ES2858315T3
(es)
|
2016-04-05 |
2021-09-30 |
Janssen Vaccines & Prevention Bv |
Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
|
|
MX2018013817A
(es)
|
2016-05-12 |
2019-03-21 |
Janssen Vaccines & Prevention Bv |
Promotor bidireccional potente y equilibrado.
|
|
IL264119B2
(en)
|
2016-05-30 |
2023-04-01 |
Janssen Vaccines Prevention B V |
f proteins of rsv are stabilized before fusion
|
|
WO2017220499A1
(en)
|
2016-06-20 |
2017-12-28 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
|
EP3484506A1
(en)
|
2016-07-14 |
2019-05-22 |
Janssen Vaccines & Prevention B.V. |
Hpv vaccines
|
|
TW201825511A
(zh)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
表現免疫檢查點調節子的溶瘤病毒
|
|
WO2018091680A1
(en)
|
2016-11-18 |
2018-05-24 |
Transgene Sa |
Cowpox-based oncolytic vectors
|
|
CN110168092A
(zh)
|
2016-12-28 |
2019-08-23 |
特朗斯吉有限公司 |
溶瘤病毒和治疗分子
|
|
BR112019015671A2
(pt)
|
2017-02-09 |
2020-04-14 |
Janssen Vaccines & Prevention Bv |
promotor potente e curto para expressão de genes heterológicos
|
|
WO2018210871A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
CA3061278A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
WO2019020543A1
(en)
|
2017-07-28 |
2019-01-31 |
Transgene Sa |
ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
|
|
US11229695B2
(en)
|
2017-09-15 |
2022-01-25 |
Janssen Vaccines & Prevention B.V. |
Method for the safe induction of immunity against RSV
|
|
WO2020011754A1
(en)
|
2018-07-09 |
2020-01-16 |
Transgene |
Chimeric vaccinia viruses
|
|
JPWO2020090871A1
(ja)
|
2018-10-30 |
2021-10-07 |
国立大学法人 東京大学 |
がん治療のための腫瘍溶解性ウイルス
|
|
TW202204380A
(zh)
|
2020-01-31 |
2022-02-01 |
美商詹森藥物公司 |
用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
|
|
AU2021237818A1
(en)
|
2020-03-19 |
2022-09-29 |
Trizell Ltd. |
Temperature-responsive virus storage system
|
|
AU2021309007A1
(en)
|
2020-07-13 |
2023-02-16 |
Transgene |
Treatment of immune depression
|
|
AU2022214006A1
(en)
|
2021-02-01 |
2023-09-21 |
St Phi Therapeutics Co., Ltd. |
Targeted protein degradation system and use thereof
|
|
JP2024509756A
(ja)
|
2021-02-19 |
2024-03-05 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
安定化された融合前ｒｓｖ ｆｂ抗原
|
|
WO2023020939A1
(en)
|
2021-08-17 |
2023-02-23 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023025899A2
(en)
|
2021-08-26 |
2023-03-02 |
Transgene |
Delivery system for targeting genes of the interferon pathway
|
|
WO2023111725A1
(en)
|
2021-12-14 |
2023-06-22 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2024003353A1
(en)
|
2022-07-01 |
2024-01-04 |
Transgene |
Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
|
|
WO2024038175A1
(en)
|
2022-08-18 |
2024-02-22 |
Transgene |
Chimeric poxviruses
|
